Histopathological study of the hepatic and renal toxicity associated with the co-administration of imatinib and acetaminophen in a preclinical mouse model

Malaysian Journal of Pathology

Volumn 32, Issue 1, 2010, Pages 1-11

  Nassar, Inthisham ^a   Pasupati, Thanikachalam ^a   Judson, John Paul ^a   Segarra, Ignacio ^a  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

Acetaminophen; Drug drug interaction; Hepatotoxicity; Histopathology; Imatinib; Renal toxicity

Indexed keywords

IMATINIB; PARACETAMOL; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; CELL DEGENERATION; CONTROLLED STUDY; CYTOLYSIS; HISTOPATHOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; LIVER CELL DAMAGE; LIVER CONGESTION; LIVER SINUSOID; LIVER TOXICITY; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; ANIMAL; DISEASE MODEL; DRUG EFFECT; DRUG INTERACTION; KIDNEY; LIVER; PATHOLOGY; TOXIC HEPATITIS;

ACETAMINOPHEN; ANALGESICS; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DRUG-INDUCED LIVER INJURY; KIDNEY; LIVER; MALE; MICE; MICE, INBRED ICR; PIPERAZINES; PYRIMIDINES;

EID: 77954653358     PISSN: 01268635     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005; 105: 2640-53.
2. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005; 44: 879-94.
3. Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Can Res. 2002; 8: 935-42.
4. Druker BJ, Guilhot F, O'Brien SG, et al. Five year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2007; 356: 2408-17.
5. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB. Abl proteintyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-kit and platelet derived growth factor receptors. J Pharmacol Exp Ther. 2000; 295: 139-45.
6. Braconi C, Bracci R, Cellerino R. Molecular targets in Gastrointestinal Stromal Tumors (GIST) therapy. Curr Cancer Drug Targets. 2008; 8:359-66.
7. Cassier PA, Dufresne A, Arifi S, et al. Imatinib mesilate for the treatment of gastrointestinal stromal tumour. Expert Opin Pharmacother. 2008; 9: 1211-22.
8. Handolias D, McArthur GA. Imatinib as effective therapy for dermatofi brosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer. Future Oncol. 2008; 4: 211-7.
9. Haberler C, Gelpi E, Marosi C, Rössler K, Birner P, Budka H, Hainfellner JA. Immunohistochemical analysis of platelet-derived growth factor receptor -alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy. J Neurooncol. 2006; 76: 105-9.
10. Leder C, Ortler S, Seggewiss R, Einsele H, Wiendl H. Modulation of T-effector function by imatinib at the level of cytokine secretion. Exp Hematol. 2007; 35: 1266-71.
11. Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, Candido R, Cooper ME. Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol. 2004; 24: 935-942.
12. Peng B, Dutreix C, Mehring G, et al. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol. 2004; 44: 158-62.
13. Nikolova Z, Peng B, Hubert M, et al. Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. Cancer Chemother Pharmacol. 2004; 53: 433-8.
14. Kretz O, Weiss HM, Schumacher MM, Gross G. In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukemia. Br J Clin Pharmacol. 2004; 58: 212-6.
15. Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF. Distribution of STI-571 to the Brain is Limited by P-Glycoprotein-Mediated Efflux. J Pharmacol Exp Ther. 2003; 304: 1085-92.
16. Gschwind HP, Pfaar U, Waldmeier F, et al. Metabolism and disposition of imatinib in healthy volunteers. Drug Metab Dispos. 2005; 33: 1503-12.
17. Ramalingam S, Lagattuta TF, Egorin MJ, et al. Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans. Pharmacotherapy. 2004; 24: 1232-5.
18. Pou M, Saval N, Vera M, Saurina A, Solé M, Cervantes F, Botey A. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma. 2003; 44: 1239-41.
19. Foringer JR, Verami RR, Tjia VM, et al. Acute renal failure to imatinib mesylate treatment in prostate cancer. Ann Pharmacother. 2005; 39: 2136-8.
20. Cross TJ, Bagot C, Portmann B, Wendon J, Gillett D. Imatinib mesylate as a cause of acute liver failure. Am J Hematol. 2006; 81: 189-92.
21. Ferrero D, Pogliani EM, Rege-Cambrin G, et al. Corticosteriods can reverse severe imantinb-induded hepatotoxicity. Haematologica. 2006; 91: e78-e80.
22. Ohyashiki K, Kuriyama Y, Nakajima A, et al. Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 2002; 16: 2160-61.
23. James C, Trouette H, Marit G, Cony-Makhoul P, Mahon F-X. Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia. 2003; 17: 978-9.
24. Kikuchi S, Muroi K, Takahashi S, et al. Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes. Leuk Lymphoma. 2004; 45: 2349-51.
25. Lin NU, Sarantopoulos S, Stone JR, Galinsky I, Stone RM, Deangelo DJ, Soiffer RJ. Fatal hepatic necrosis following imatinib mesylate therapy. Blood. 2003; 102: 3455-6.
26. Thia TJK, Tan HH, Chuah THC, Chow WC, Lui HF. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. Singapore Med J. 2008; 49: e86-e89.
27. Christo PJ, Mazloomdoost D. Cancer pain and analgesia. Ann N Y Acad Sci. 2008; 1138: 278-98.
28. Stockler M, Vardy J, Pillai V, Warr D. Acetaminophen (Paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: A randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol. 2004; 22: 3389-94.
29. Nassar I, Pasupati T, Judson JP, Segarra I. Reduced exposure of imatinib after coadministration with acetaminophen to mice. Ind J Pharmacol. 2009; 41: 167-72.
30. Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis 2007; 11: 525-48.
31. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002; 99: 1928-37.
32. Ridruejo E, Cacchione R, Villamil AG, Marciano S, Gadano AC, Mando OG. Imatinib-induced fatal acute liver failure. World J Gastroenterol. 2007;13: 6608-11.
33. Mazer M, Perrone J. Acetaminophen-induced nephrotoxicity: pathophysiology, clinical manifestations, and management. J Med Toxicol 2008; 4: 2-6.
34. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003; 384: 994-1004.
35. Ghosh A, Parames C. Anti-oxidative effect of a protein from cajanus indicus L against acetaminophen-induced hepato-nephro toxicity. J Biochem Mol Bio 2007; 40: 1039-49.
36. Manov I, Bashenko Y, Hirsh M, Iancu TC. Involvement of the multidrug resistance Pglycoprotein in acetaminophen-induced toxicity in hepatoma-derived HepG2 and Hep3B cells. Basic Clin Pharmacol Toxicol 2006; 99: 213-24.
37. Ikuta K, Torimoto Y, Jimbo J, et al. Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management. Int J Hematol. 2005; 82: 343-6.
38. Ikeda K, Shiga Y, Takahashi A, et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma. 2006; 47: 155-7.
39. Kong JH, Yoo SH, Lee KE, et al. Early imatinibmesylate- induced hepatotoxicity in chronic myelogenous leukaemia. Acta Haematol. 2007; 118: 205-8.